The Ins and Outs of Cerebral Malaria Pathogenesis: Immunopathology, Extracellular Vesicles, Immunometabolism, and Trained Immunity

Frederic Sierro 1,2† and Georges E. R. Grau 1*

1 Vascular Immunology Unit, Department of Pathology, Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia, 2 Human Health, Nuclear Science, Technology, and Landmark Infrastructure, Australian Nuclear Science and Technology Organisation, Sydney, NSW, Australia

Complications from malaria parasite infections still cost the lives of close to half a million people every year. The most severe is cerebral malaria (CM). Employing murine models of CM, autopsy results, in vitro experiments, neuroimaging and microscopic techniques, decades of research activity have investigated the development of CM immunopathology in the hope of identifying steps that could be therapeutically targeted. Yet important questions remain. This review summarizes recent findings, primarily mechanistic insights on the essential cellular and molecular players involved gained within the murine experimental cerebral malaria model. It also highlights recent developments in (a) cell-cell communication events mediated through extracellular vesicles (EVs), (b) mounting evidence for innate immune memory, leading to “trained” increased or tolerised responses, and (c) modulation of immune cell function through metabolism, that could shed light on why some patients develop this life-threatening condition whilst many do not.

Keywords: cerebral malaria (CM), immunopathology, extracellular vesicle (EV), Immunometabolism, trained immunity

INTRODUCTION

Among protozoan parasites of the genus *Plasmodium*, seven species are able to infect humans to cause malaria. The two major species are *Plasmodium vivax* and *Plasmodium falciparum*, with the former accounting for the most cases and the latter being responsible for the majority of deaths (1). Plasmodia are dual host parasites (mosquito and mammals) and within the mammalian host, broadly two hepatic stages and one blood stage are defined. Malaria induces a wide spectrum of symptoms and signs which differ between affected individuals, for example, between adults and children. In 1–2% of cases however (2), infection leads to severe malaria that exclusively develops during the blood stage of the malaria parasite cycle. Severe malaria can include the following disturbances, singly or in combination: electrolyte and metabolite imbalance, severe anemia, pulmonary oedema with respiratory distress, jaundice, and its most severe manifestation: cerebral malaria (CM). CM is characterized by, seizures, coma, and death.
In endemic regions of Africa, CM mostly affects children under the age of five while in Southeast Asia, it is observed mostly in young adults. CM lethality still is in the range of 15–25% with the best available treatments (3). Over 25% of survivors from CM are afflicted by life-long sequelae including sensory and cognitive impairment (4), epilepsy and physical disability. Thus, despite incremental progress in more than a century since the discovery of the malaria parasite, a deep understanding of this disease and its deadliest complication, CM, is far from complete, and development of effective therapies remains a high priority.

A comprehensive appraisal of the histopathology associated with CM or experimental animal models of CM, as well as its changes following characterized interventions, constitute a valid experimental approach to identify targetable disease development stages, cellular or molecular players. This could eventually lead to the identification of adjunctive therapies. Investigating the histopathology and pathophysiology of HCM (human cerebral malaria) in patients has ethical and technical constraints since pathological analysis of brain and most other tissues besides blood are limited to post-mortem observations. Thus, models of experimental cerebral malaria (ECM), caused by infection of susceptible mice with Plasmodium berghei ANKA (PbA), have provided important clues. ECM and HCM have more than twenty documented shared pathological features (5, 6). In both humans and mice, early lesions involve binding of infected erythrocytes (IE) to the brain microcirculation (7), albeit this is a minor feature in ECM compared to HCM. More recently the presence of IE in ECM has been confirmed (8), and found to correspond with development of vascular leakage. A cascade of sequestration of various leukocyte subtypes, including monocytes, macrophages, NK cells, CD4+ and CD8+ T cells, then ensues. In ECM, CD8+ T cells are eventually responsible for endothelial damage and the subsequent breakdown of the blood-brain barrier (BBB). In both patients and mice, neurological signs progress from seizures, ataxia and paralysis to coma and eventual death, and both are associated with brain oedema and hemorrhages.

In this review, we summarize the consensus and controversies surrounding the sequence of cellular events leading to the development of vascular neuropathology in experimental CM (ECM) and their correlates in human CM (HCM). Numerous aspects of the similarities and differences between HCM and ECM have been reviewed (5, 6, 9–13), clearly stating the limitations as well as the strengths of mouse model. A consensus paper about these issues has been published (14). Other recent findings in HCM have been detailed and discussed (15). We also highlight recent investigations extending beyond the targeting of specific cell types (e.g., monocyte subsets) into potential modulators or effectors of CM such as extracellular vesicles, diet, immunometabolism and trained immunity.

**SEQUENCE OF EVENTS LEADING TO CM IMMUNOPATHOLOGY**

Both HCM and ECM are associated with a sequential and marked accumulation of various immune cell subtypes in the brain microcirculation but histological studies paint somewhat different pictures between them. In ECM, a number of studies have provided evidence for an early requirement for CD4+ and for a late accumulation of CD8+ T cells while for other accumulating cell types, there are still controversies as to direct pathogenic roles (5, 6, 16, 17). HCM is characterized by a disease spectrum in children that differs from what is observed in adults. Three disease categories have been defined in pediatric HCM (CM1, CM2, and CM3) (18), occurring in 15, 56, and 29% of clinically defined cases, respectively. CM1 patients only display IE sequestration, whereas patients with CM2 have IE sequestration associated with other intra- and perivascular pathology, including immune cell infiltrates. Patients with CM3 fulfill the complete World Health Organization clinical criteria for CM, including unarousable coma associated with infection, but died of non-malarial causes. In South-East Asian adult patients, mainly IE sequestration has been observed (19). Here we summarize the elucidated sequence of these cellular events and the proposed roles attributed to different cell types.

**ACTIVATION OF ENDOTHELIAL CELLS AND SEQUESTRATION OF INFECTED ERYTHROCYTES AND PLATELETS**

A hallmark in HCM post-mortem observations is the distension of cerebral capillaries and venules containing IE and platelets. This sequestration involves predominantly late stage IE and is considered an immune evasion mechanism, as it removes mature stages of the parasites form the circulation. It is accompanied by systemic endothelial activation with upregulation of markers of endothelial cell (EC) activation such as ICAM-1, E-Selectin, CD36, and von Willebrand Factor (vWF), that all can serve as adhesion molecules for IE. Platelets are now considered key contributors to CM by providing an alternate, indirect mechanism for IE cyoadhesion (20). This is achieved by forming bridges between IE and ECs at sites of low endothelial adhesion molecule expression, as shown in vitro (21, 22). These in vitro results have been confirmed by the demonstration of intravascular platelet accumulation in HCM, as shown in Malawian (3, 23) and South-East Asian (19) patients. Aside from this pathogenic role, platelets can exert a protective effect in malaria, as shown in vitro (24) and in vivo (25, 26). More recently, these in vivo results have been challenged, both in vitro using P. falciparum IE and in vivo using P. chabaudi and P. berghei-infected mice. Results indicate platelets do not kill blood-stage Plasmodium at physiologically relevant effector-to-target ratios. Furthermore, adoptive transfer of wild-type platelets to CD40-KO mice, which are resistant to ECM, partially restored ECM mortality and signs in CD40-KO recipients, indicating platelets are integral to the pathogenic process, and platelet CD40 is a key molecule (27), confirming 2002 data of Piguet et al. (28), vide infra. Sequestration of IE and platelets during ECM was originally disputed but further observations have also documented these as key pathogenic elements, as are the associated activation of ECs and upregulation of adhesion molecules.
This central and initiating EC-driven element of CM pathology is modulated by cytokines such as interferon-γ, TNF (previously called TNF-alpha) and lymphotoxin (previously called TNF-beta) (5). High levels of pro-inflammatory cytokines, in particular TNF, have been detected in the blood and the brain of patients who succumbed from CM as well as in models of ECM (29). Further supporting evidence has been provided for this scenario: in vitro, exposure to TNF induces upregulation of EC activation markers and IE pro-adhesion factors, and leads to increased IE binding on isolated human (30) or murine (31) brain microvascular cells.

**IMMUNE CELL ACCUMULATION**

Subsequent to the accumulation of IE and platelets, the intravascular accumulation of leucocytes is considered a key step in the development of ECM (32) and in some cases of HCM (3, 19, 23, 33). In ECM, this accumulation of host leucocytes in the brain microvasculature is correlated with the onset and severity of neurological signs and is thus considered to be largely responsible for neurological damage. While these immune subsets have been shown to mainly comprise monocytes, T cells and natural killer (NK) cells, their accumulation sequence and the relative pathological role of these and other cell subsets remain debated (Figure 1).

Numerous ECM studies suggest that accumulation of T cells (both CD8+ and CD4+) cells in the brain of infected mice have major pathogenic roles. Supporting evidence has been obtained through anti-CD4 or anti-CD8 antibody depletion strategies (34, 35) just before or after the detection of neurological signs, or through the use of genetically deficient mice lacking functional CD8+ T cells (32, 36, 37). In these models, infected animals failed to develop ECM, or showed a reduction in the severity of the syndrome. RAG2-KO mice that have been shown to be resistant to ECM can develop this pathology following adoptive transfer of CD8+ T cells isolated from PlA-infected ECM-susceptible WT mice. Furthermore, transfer of cells originating from perforin- or granzyme B-deficient mice does not result in ECM development, indicating an essential role for these cytotoxic molecules and supporting an effector function for CD8+ T cells. On the other hand, CD4+ T cell involvement in ECM pathogenesis appears to take on a helper role, as in the majority of studies and mouse strains used, their antibody-mediated depletion only prevents ECM development when performed before or early after infection (5, 34, 38, 39).

Evidence has documented a requirement for a concomitant presence of both T cells and IE for ECM development (40) as, in brains of mice infected with a parasite not causing CM, accumulation of CD8+ T cells is still present but no IE sequestration is observed. Conversely, experimental depletion or blockade of T cell accumulation in ECM models correlates with a diminution of IE accumulation (38, 41). While the proportion of sequestered T cells that are parasite antigen-specific is not known, parasite antigen-specific T cells do sequester within brain microvessels during ECM (42). Blockade of the adhesion molecule LFA-1 in a therapeutic setting (i.e., after onset of clinical signs) has been shown to be effective in blocking ECM and promoting survival (43, 44). A recent study confirms these earlier observations and provides a potential mechanism by showing that late, combined administration of antibodies specific for VLA-4 and LFA-1 decreases CD8+ T cell adhesion and numbers in cerebral blood vessels (39). Altogether, a current paradigm favors a mechanism involving high systemic levels of certain cytokines such as IFN-γ and TNF as well as binding of IE to brain vasculature. Both activate ECs which further increase binding of IE and allow recruitment and binding of T cells. These events participate in cross-presentation of malarial antigens accumulated on the luminal surfaces of cerebral blood vessels with parasite-specific CD8+ T cells previously primed in the periphery. These CD8+ T cells then cause local damage to the endothelium through cytotoxic mechanisms with ensuing BBB breakdown and neurological damage (30, 45).

While the view that T cells have a central role in ECM pathogenesis is undisputed, its translation to the human disease is less clear as there is little evidence for high numbers of CD8+ T cells in HCM. In ECM, this CD8+ T cell-centric model follows a neat sequence of events, but still presents some mechanistic gaps. Thus, several other cell types have been investigated and have been shown to be critically important. For example, local cross-presentation of parasite-derived antigens is unlikely to be performed by IE as they are devoid of MHC molecules. Several reports have suggested that activated ECs could perform this function after transfer of malarial antigens (30, 46–48). Others have repositioned myeloid cells in the spotlight, particularly intravascular sequestered monocytes that have long been reported in both HCM (3, 23, 33, 49, 50) and ECM (29). In ECM, we have shown, using intravital two-photon microscopy, that monocytes start accumulating in the brain several days prior to the onset of clinical signs (51). As the severity of the disease increases, slower rolling speed and increased adhesion of monocytes is directly observed in correlation with EC activation. Using high-dimensional flow cytometry we have calculated that at the onset of clinically-overt CM in mice, CD11b+ cells constitute ~80% of accumulating leukocytes in the brain vasculature at a time when T cells, B cells, neutrophils, DC, and NK cells remain numerically minor (52). Decreased ECM signs and pathology after global monocyte/macrophage depletion by clodronate liposomes (53) or after the abrogation of inflammatory monocyte recruitment by anti-CCR2 antibody (53) support a pathogenic role of these cells. The exact mechanisms by which inflammatory monocytes are involved in ECM pathogenesis still remain to be ascertained. Naturally, monocytes constitute a major source of cytokines and chemokines in CM pathogenesis and locally arrested monocytes could potentiates brain EC activation and recruitment of other leukocytes, notably CD8+ T cells. We have confirmed this by showing the interdependent recruitment of monocytc cells and CD8+ T cells to the central nervous system (51). Monocytes have the potential to differentiate into macrophage- or dendritic cell (DC)-like phenotypes. A recent study has reported that the majority of CD11b+ cells whose numbers peak at the onset of ECM symptoms also express CD11c, F4/80 and high levels of MHCII. These authors conclude that
these are inflammatory monocytes that differentiate into splenic monocyte-derived DCs and are then subsequently recruited to the central nervous system (54). As opposed to resident macrophages and conventional DCs, a clear delineation between monocyte-derived DCs and monocyte-derived macrophages is still hotly debated, as extensively reviewed elsewhere (55). Recently, we have applied multiparametric high dimensional analysis using t-distributed stochastic neighbor embedding (tSNE) to further characterize the cerebral CD11b<sup>+</sup> populations in ECM. This has allowed us to identify a population of non-resident Ly6C<sup>lo</sup> cells with a monocyte/macrophage phenotype as the most prevalent population in the CM brain vasculature at peak disease. Importantly, we have further demonstrated that these monocytes derive from Ly6C<sup>hi</sup> precursors and are pathogenic. Indeed, immune-modulatory particles (IMP)—previously shown to specifically target Ly6C<sup>hi</sup> precursors and induce their sequestration in the spleen (56)—dramatically reduce CD11b<sup>+</sup>Ly6C<sup>lo</sup> numbers in the brain and protect against cerebral and pulmonary lesions, with evidence of a down-modulation of immunopathology (52). Moreover, we have shown that when used in combination with established anti-malarial drugs, IMP treatment is highly effective (88% survival) even when given after neurological signs are present.

In addition to their protective role during malaria (57), γδ T cells have also been suggested as contributors to pathogenesis as they were found in patients (58), to be one of the predominant sources of cytokines and chemokines associated with severe malaria (50). Protection from ECM development following antibody-mediated depletion of γδ T cells supports this notion (59). However, γδ T cell depletion only prevents ECM development when performed before or early post infection, and such an effect is not observed in mice genetically deficient in γδ T cells.

Subsets of innate lymphoid cells (ILC) have been suggested to have distinct roles in CM. While expansion of ILC2 prevents ECM via a mechanism dependent on M2 macrophages and T regulatory cells (60), there is evidence that ILC1, through their cytotoxic NK subset, are involved in pathogenesis (61). However,
once again, NK cell depletion prevents ECM, but only in a prophylactic setting.

Thus, while targeting many immune cell types prevents the development of ECM, it is only the direct targeting of CD8+ T cells or of monocytes that has shown therapeutic effectiveness. The highly effective late stage success of the combination treatment with IMP and established anti-malarial drugs (52) highlights the novel potential of immunomodulatory targeting of innate immune cells in addition to CD8+ T cells in severe malaria, with a potential avenue for human translation where the role of CD8+ T cells is still unclear.

**EXTRACELLULAR VESICLES: BOTH IMMUNOMODULATORS AND EFFECTORS OF PATHOLOGY**

A hint of a role of membrane microvesicles (originally called microparticles) in immunopathology was adduced from experiments in which we attempted to understand the effector mechanisms of TNF in microvascular damage. Among these was the demonstration that TNF dose-dependently enhanced the release of microvesicles by endothelial cells (62). In parallel, microvesicles were found to be overproduced in the mouse model of CM. The majority of these microvesicles were from platelet origin, and seemed to be of pathogenic importance. Treatment of infected mice with an anti-CD40L mAb reduced microvesicle levels and thrombocytopenia, suggesting that CD40L is the main effector of malarial-induced thrombocytopenia. A role for platelet caspases in vivo was demonstrated by treatment of infected mice with the caspases inhibitor ZVAD-fmk, which reduced CM-associated mortality (28).

We subsequently found high microvesicle levels in the plasma of Malawian patients with CM. Remarkably, these high plasma levels were not seen in patients with severe malarial anemia, suggesting a relationship between microvesicle overproduction and the neuropathology (18). Since then, evidence has emerged that an important part of the immunopathological reaction is the release of extracellular vesicles, notably microvesicles (6) (Figure 1). Indeed, an effector role for microvesicles in immunopathogenesis is supported by the following evidence: (1) microvesicles can alter endothelial cell phenotype and function (63). (2) microvesicles are strong pro-inflammatory elements (64). (3) interfering with microvesicle binding to target cells reduces their activation (65), and (4) passive i.v. transfer of purified microvesicles exacerbates the disease in malarial-infected mice, and in vitro generated endothelial microvesicles even trigger CM-like lesions in naïve recipients (13).

We have found that ABCA1 deletion, which perturbs microvesicle release (66), fully protects mice against CM (67). Furthermore, blocking microvesicle production pharmacologically is beneficial for endothelial integrity (68, 69) and can prevent mortality due to ECM (70). Of note is that not only host-derived microvesicles appear important in CM: we have also shown that microvesicles released by malaria-infected erythrocytes in vivo are strongly pro-inflammatory in ECM, as evidenced by increased TNF production and CD40 expression on macrophages (64). This finding is not restricted to the experimental mouse model: plasma levels of erythrocytic microvesicles also are elevated in CM patients (71, 72).

Additionally, microvesicles have the potential to participate in antigen presentation, to express accessory molecules (48) and to amplify T cell proliferation, a property that we also had demonstrated in the context of TB (73). These results, together with those of Ramachandra et al. (74), suggest that microvesicles can be immunomodulatory elements, in addition to their effector roles in immunopathogenesis.

The involvement of microvesicles in CM remains incompletely understood because flow cytometry presents some limitations for their quantitation and characterization (75). Plasma microvesicles appear to carry discrete sets of miRNAs in relation to CM development (76). Malaria parasites themselves directly lead to the release of EV that contain small regulatory RNAs (77). Other aspects indicating a wider involvement of extracellular vesicles in malarial pathogenesis have been recently reviewed (78, 79).

**IMMUNOMETABOLISM AND CM DEVELOPMENT**

The switch from oxidative phosphorylation to aerobic glycolysis and glutaminolysis was first described by Otto Warburg close to a century ago in the case of rapidly proliferating cancer cells (80). Since then it has become clear that reprogramming of transcriptional but also metabolic programs is a required intrinsic cellular adaptation to adjust tissue function in response to stresses. Injury and/or repair responses have been shown to drive metabolic changes to accommodate increased or specific demands. Proper organismal metabolic state adjustment is considered critical in maintaining disease tolerance while maladaptation is seen as contributing to pathology or long-term sequelae. These metabolic changes can be triggered by a plethora of signals such as certain cytokines or hypoxia. The mechanistic target of rapamycin complex 1 (mTORC1), a protein kinase complex expressed in most eukaryotic cells, is considered a critical signaling integrator that links these stimuli as well as nutrient sensing to the coordinated regulation of cellular metabolism (81, 82).

Following a seminal paper demonstrating that the co-stimulation of T cells with anti-CD28 increased glucose uptake and glycolysis (83), the same principles of metabolic reprogramming have been shown to be as critical in other immune cells in response to cytokines, antigens (84) or pathogen-associated molecular patterns (PAMPs) (85) and damage-associated molecular patterns (DAMPs).

In turn, the metabolic status at the cellular level affects and constrains cellular functional polarization, e.g., in key developmental steps or in pro- vs. anti-inflammatory polarization of immune cells. One of the mechanisms highlighted is the potential role of some metabolites as stabilizers for transcription factors such as in the case of succinate build up following OXPHOS disruption acting as an inflammatory molecular switch through stabilization of HIF1-α. This
realization has resulted in a partial re-definition and extension of the field of immunometabolism from well-known regulatory roles of the immune system on local and systemic metabolism (tissue immunometabolism) to the additional modulatory role of cell intrinsic metabolic pathways on immune functions (cellular immunometabolism) [reviewed in (86)].

For example, it has been increasingly appreciated that T cell activation results in metabolic reprogramming from oxidative phosphorylation (OXPHOS) to glycolysis to meet the increased energetic and biosynthetic demands for T cell expansion and effector functions (87, 88). It was also conceived that promotion of effector cell differentiation, memory recall response or, on the contrary, regulatory phenotypes can be achieved by shifting their metabolism through changes in the availability of specific nutrients such as glucose or short chain fatty acids (SCFAs) (89, 90). In the case of monocytes/macrophages, the common view is that glycolysis supports inflammatory phenotypes or is favored after activation (91), while OXPHOS, presumably for sustained energy production, is a feature of resting monocytes/macrophages or macrophages with anti-inflammatory phenotypes. However, recent developments imply a more complex situation as glucose metabolism is still required in both anti-inflammatory and inflammatory macrophages (92, 93) and OXPHOS can also drive inflammasome activation in inflammatory macrophages (94).

Significant metabolic changes such as hypoglycaemia and lactic acidosis as well as perturbations in amino acid metabolism have long been observed in severe malaria in both ECM (95–97) and HCM (98–100). High brain concentrations of lactate, alanine, and glutamine are present in mice developing ECM but not in mice resistant to ECM (95, 101). We have demonstrated that elevated lactate was not uniform but occurred at the site of immunopathology, and that malaria parasites were not the dominant source of elevated lactate (102). These metabolic changes are consistent with, and have been mainly attributed to the occurrence of hypoxia/ischaemia that follows obstruction of brain microvessels as in the case of ECM, both types of oedema, namely cytotoxic, and vasogenic oedema, have been demonstrated (97).

However, the recent developments in our understanding of immunometabolism mentioned above have called for a reassessment of hypotheses on mechanisms leading to CNS metabolite changes during CM development. It had been observed for some time that dietary restriction could prevent development of ECM, although only in a prophylactic setting (103, 104). Several recent studies have provided mechanisms on how manipulation of metabolism could explain this phenomenon. In independent studies, Gordon et al. (105) and Mejia et al. (106) demonstrated that caloric restriction or treatment with rapamycin, an inhibitor of mTOR, blocked the development of ECM. Remarkably, another study (107) showed that manipulating the glutamine pathway using the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) rescues mice from ECM even when administered late in the infection. While the mechanisms proposed for these observations relate to blocks in activated T cell metabolism, few changes were observed in the numbers of T cells and other leucocytes recruited to the brain, and thus effects on other immune or mesenchymal cells remain a possibility. Indeed, a more recent report has shown that inhibition of glycolysis using the competitive glucose analog 2-deoxy glucose [2DG] was protective in ECM, not through effects on parasitaemia, the extent of anemia, the degree of cerebral oedema, or neuroinflammation but rather through modulation of haemostasis (108). These recent results emphasize the contribution of altered metabolic regulation to ECM and, more generally, to malarial pathogenesis in mice. The exact mechanisms behind these effects, the main cellular players involved, as well as their validation in HCM still requires investigation.

Because metabolic reprogramming can occur in response to changes in nutrient and oxygen availability, and in response to cytokines or other immune receptor stimulation, it presents the opportunity to therapeutically target these mechanisms at different levels, such as through dietary intervention. For example, pre-exposure to a high-fat diet reduced ECM via a mechanism that involved antioxidants (109). Another exciting prospect is the potential role of EVs in mediating such metabolic reprogramming. EVs could modulate metabolic pathways by virtue of transfer of miRNAs, mRNAs, proteins, and packaged metabolites to target cells. Such mechanisms have been described in response to other challenges such as retemplating of hepatic metabolic pathways through muscle-derived exosomes following intense exercise (110). As developed above, MVs and, to a lesser extent, exosomes are an essential component of CM development in both ECM and HCM but such link between the release of MVs in CM and immunometabolism regulation remains to be investigated.

"INNATE IMMUNE MEMORY" AND TRAINED IMMUNITY IN CM DEVELOPMENT

"Trained immunity" is defined as the capacity of some innate immune cells such as monocytes/macrophages to display an enhanced or polarized immune response upon non-specific restimulation (111). Mechanistic studies have highlighted long-term epigenetic changes as being largely responsible for this phenomenon or the converse, the situation where a previous trigger leads to a decreased responsiveness to a subsequent immune challenge [reviewed in (112)]. These recent observations have cemented the long-proposed concept of "innate immune memory" (113, 114). The increased proinflammatory cell programs characterizing trained immunity or, on the contrary, "tolerised" innate immune phenotypes are associated with changes in cellular metabolism such as the metabolic shift from OXPHOS toward glycolysis occurring in Candida albicans-derived ß-glucan-induced trained immunity (111, 115).

An important recent discovery is the observation that metabolites such as succinate and fumarate can serve as modulators of epigenetic enzymes such as histone and DNA demethylases (116). Thus, the buildup of these TCA cycle metabolites or some derivatives such as acconitate (117) following OXPHOS disruption has been proposed to play a
major role in innate immune memory. Such a link between metabolic reprogramming and trained immunity has the potential to provide novel insights into the pathogenesis of several diseases. Therefore, ongoing research is seeking to understand how innate immune memory, in some cases via immunometabolic modulation, could provide enhanced protection against reinfection, heterologous benefits against unrelated pathogens or on the contrary increase risks of post infection host-mediated pathology and increased susceptibility to chronic inflammatory diseases.

While beyond the scope of this manuscript, a large number of epidemiological studies have shown that outcomes of malarial infections are influenced by age and previous exposure. Furthermore, in specific resistant or susceptible ethnic groups where frequencies of single nucleotide polymorphisms (SNPs) in classical malaria-resistance genes cannot explain interethnic differences, epigenetic modifications or different chromatin landscapes were observed on specific host gene promoters or host genes that provide resistance to or susceptibility to malaria (118–121). In this context, there is also growing evidence that parasite infection can induce a state of trained innate immunity as exemplified by the hyperresponsiveness to TLR ligand stimulation of peripheral blood mononuclear cells (PBMCs) from patients with acute febrile disease in vitro (122). Additionally, higher numbers of IFN-γ producing PBMCs obtained following P. falciparum peptide stimulation in children suffering from malaria were correlated with significantly lower rates of malaria reinfection (123, 124). Approaches using controlled human malarial infections or vaccine trials have reported the induction of memory-like NK cells able to produce IFN-γ upon recall with malarial antigen or vaccine peptides. (125–127). A recent study has shown that PBMCs previously exposed to P. falciparum display an enhanced response to subsequent TLR2 stimulation and that this hyperresponsiveness correlated with increased methylation at specific proinflammatory and immunometabolic promoters. Importantly, these epigenetic modifications were also seen in Kenyan children infected with malaria (121). To our knowledge, there is no report of a direct link between trained immunity and CM. However, it is reasonable to hypothesize that such enhanced response training, although beneficial in fighting the parasite and assisting adaptive immunity, may increase the risk of severe disease upon reinfection. On the other hand, multiple episodes of malarial infection could instead induce tolerance to subsequent infection through modulation of this innate immune memory (Figure 1).

Much work remains to be done in order to integrate the interactions between immunologic signals, metabolic changes and epigenetic modifications with long-term changes in “innate immune memory” in response to malaria. Deciphering these mechanisms could have far reaching implications. It could help predict the risk of developing CM in individuals with previous (including in utero) malarial exposure. Modulation of trained immunity would also influence the clinical development of rationally designed malaria vaccines. Finally, this knowledge may help re-train innate cells during or before the disease to prevent severe complications. One could imagine that EVs may provide a way to achieve this by shuttling a designed cargo of miRNAs, epigenetic modifying enzymes or metabolites.

CONCLUSION AND FUTURE DIRECTIONS

The ECM model has produced a wealth of information on CM pathogenesis in mice with the aim to find an adjunctive therapy for HCM but its validity has been questioned. However, several investigators have provided a critical and evidence-based defense of this model (17, 128–131) and from knowledge gained from it, numerous laboratories have tested preclinical therapeutic interventions. Many have demonstrated efficacy at blocking the development of ECM but disappointingly, in a majority of cases, this was only found when administered before or early post infection and prior to the onset of clinical neurological signs. Therefore, only a few can justify, as therapies, a large-scale evaluation in HCM. A rare case of efficacy of treatment even when administered after the onset of clinical signs in the ECM model is the injection of IMP (52). The only other studies to date having demonstrated treatment efficacy after the onset of ECM have targeted CD8+ T cell binding to endothelial cells, and finally, immunometabolism. These successes have renewed hopes that the mouse model of ECM will continue to bring novel ideas/concepts which then will need to be confirmed or infirmed in HCM. For example, the characterization of retinal pathology in ECM (132) and (133), which was followed by the demonstration of its usefulness in HCM (134–137) (and many others) or MRI findings of brain alterations, originally described in 2005 for ECM (97), and followed by similar findings in HCM (138, 139).

In addition, it should be emphasized that the massive reduction in malaria burden achieved in the last two decades was mostly a result of prevention strategies rather than treatment. In this context, knowledge gained from ECM studies should not be seen as limited to the design of therapies but could also guide the expansion of our arsenal for HCM prevention. In particular, understanding changes in innate immune memory preconditioning and metabolic status in populations with high or low incidence of HCM could present opportunities for prevention through environmental or dietary interventions.

AUTHOR CONTRIBUTIONS

This review was co-written by FS and GG.

ACKNOWLEDGMENTS

This work was supported by grants of the National Health & Medical Research Council of Australia and of the Australian Research Council. We thank Dr. Sue Mei Lau for critical reading of the manuscript.
REFERENCES

1. WHO. *World Malaria Report*. Geneva: World Health Organization (2016).
2. Idro R, Ndiritu M, Ogutu B, Mwilihani S, Maitland K, Berkley J, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. *JAMA*. (2007) 297:2232–40. doi: 10.1001/jama.297.20.2232
3. Hochman SE, Madaline TF, Wassmer SC, Mbale E, Choi N, Seydel KB, et al. Fatal pediatric cerebral malaria is associated with intravascular monocytes and platelets that are increased with HIV coinfection. *MBio*. (2015) 6:e01390–15. doi: 10.1128/mBio.01390-15
4. John CC, Bagiringa P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Cerebral malaria in children is associated with long-term cognitive impairment. *Pediatrics*. (2008) 122:e92–9. doi: 10.1542/peds.2007-3709
5. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. *Trends Immunol.* (2003) 24:491–9. doi: 10.1016/S1471-4906(03)00229-1
6. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. *Nat Rev Immunol.* (2005) 5:722–35. doi: 10.1038/nri1686
7. Hearns J, Raymont N, Landon DN, Kats DR, de Souza JB. Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. *Infect. Immun.* (2000) 68:3564–76. doi: 10.1128/IAI.68.9.3564-3576.2000
8. Strangward P, Haley MJ, Shaw TN, Schwartz JM, Gregor D, Mironov A, et al. A quantitative brain map of experimental cerebral malaria pathology. *PLoS Pathog.* (2017) 13:e1006267. doi: 10.1371/journal.ppat.1006267
9. Colloto N, Combes V, Hunt NH, Grau GE. Cerebral malaria – a neurovascular pathology with many riddles still to be solved. *Curr Neurovasc Res.* (2004) 1:91–110. doi: 10.2174/156720404380116
10. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE. A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. *Trends Parasitol.* (2006) 22:503–8. doi: 10.1016/j.pt.2006.09.002
11. Combes V, Guillen GI, Chan-Ling T, Hunt NH, Grau GE. The crossroads of neuroinflammation in infectious diseases: endothelial cells and astrocytes. *Trends Parasitol.* (2012) 28:311–9. doi: 10.1016/j.pt.2012.05.008
12. El-Assaad F, Combes V, Hunt NH, Grau GE. Experimental models of microvascular immunopathology: the example of cerebral malaria. *J Neuroinfect Dis.* (2014) 5:134. doi: 10.4172/2314-7326.1000134
13. El-Assaad F, Thewy J, Hunt NH, Grau GE, Combes V. Production, fate and pathogenicity of plasma microparticles in murine cerebral malaria. *PLoS Pathog.* (2014) 10:e1003839. doi: 10.1371/journal.ppat.1003839
14. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, Barnwell JW, et al. The Role of Cell Adhesion in Evasion of Human Plasmodium falciparum. *Science*. (2009) 323:797–800. doi: 10.1126/science.1166296
15. McMorran BJ, Marshall VM, de Graaf C, Drysdale KE, Shaheen M, Smyth GK, et al. Platelets kill intravascularly Malarial parasites and mediate survival to infection. *Science*. (2009) 323:797–800. doi: 10.1126/science.1166296
16. McMorran BJ, Vezzorski L, Drysdale KE, Chan JA, Huang HM, Smith C, et al. Platelet factor 4 and Duffy antigen required for platelet killing of *Plasmodium falciparum*. *Science*. (2012) 338:1348–51. doi: 10.1126/science.1232899
via luminal antigen-specific engagement of brain vasculature. PLoS Pathog. (2016) 12:e1006022. doi: 10.1371/journal.ppat.1006022.

40. McMullin JA, Mitchell AJ, Ho YF, Combes V, Ball HJ, Golenser J, et al. Coincident parasite and CDS+ T cell sequestration is required for development of experimental cerebral malaria. Int J Parasitol. (2011) 41:155–63. doi: 10.1016/j.ijpara.2011.08.003.

41. Baptista FG, Pamplona A, Pena AC, Mota MM, Pied S, Vigario AM. Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect Immun. (2010) 78:4033–9. doi: 10.1128/IAI.00079-10.

42. Lundie RJ, de Koning-Ward TF, Davey GM, Camoin J, Sahatciu O, Ball HJ, et al. Blood-stage Plasmodium infection induces CDS1+ T lymphocytes to parasite-expressed antigens, largely regulated by CD4+ T+ dendritic cells. Proc Natl Acad Sci USA. (2008) 105:14509–14. doi: 10.1073/pnas.0806727105.

43. Falanga PB, Buch E. Late treatment with anti-LFA-1 (CD11a) antibody prevents cerebral malaria in a mouse model. Eur J Immunol. (1991) 21:2259–63.

44. Grau GE, Poinaire P, Piguet PF, Resina C, Rosen H, Stamenkovic I, et al. Late administration of monoclonal antibody to leukocyte function-antigen 1 in patients with murine cerebral malaria. Eur J Immunol. (1991) 21:2265–7. doi: 10.1002/eji.1830210939.

45. Howland SW, Poh CM, Renia L. Activated brain endothelial cells cross-present malaria antigen. PLoS Pathog. (2015) 11:e1004963. doi: 10.1371/journal.ppat.1004963.

46. Howland SW, Poh CM, Gun SY, Claser C, Mallaret B, Shastri N, et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO Mol Med. (2013) 5:984–99. doi: 10.1002/emmm.201202273.

47. Wheway J, Obeid S, Couraud PO, Combes V, Grau GE. The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation. PLoS ONE. (2013) 8:e52586. doi: 10.1371/annotation/9791917-c831-4c8c-9dfb-3ad7b21c667.

48. Wheway J, Latham SL, Combes V, Grau GE. Endothelial microparticles interact with and support the proliferation of T cells. J Immunol. (2014) 193:3378–87. doi: 10.4049/jimmunol.1303431.

49. Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. Am J Trop Med Hyg. (1991) 44:168–75. doi: 10.4269/ajtmh.1991.44.168.

50. Stanisic DJ, Cutts J, Eriksson E, Fowkes FJ, Rosanas-Urgell A, Siba P, et al. Gammadelta T lymphocytes to erythrocytic cycle: gammadelta T cells target the red blood cell-invasive merozoites. Blood. (2011) 118:6952–62. doi: 10.1182/blood-2011-08-376111.

51. Hviid L, Kurtzhals JA, Dodoo D, Rodrigues O, Romm A, Commye JO, et al. The gammadelta T cell response to Plasmodium falciparum malaria in a population in which malaria is endemic. Infect Immun. (1996) 64:4359–62.

52. Yanze DM, Batchelder J, van der Heyde HC, Manning DD, Weidanz WP. Gamma delta T-cell function in pathogenesis of cerebral malaria in mice infected with Plasmodium berghei ANKA. Infect Immun. (1999) 67:446–8.

53. Besnard AG, Guabiraba R, Niedbala W, Palomo J, Reverchon F, Shaw TN, et al. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog. (2015) 11:e1004607. doi: 10.1371/journal.ppat.1004607.

54. Hansen DS, Bernard NJ, Nie CQ, Schofield L, NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol. (2007) 178:5779–88. doi: 10.4049/jimmunol.178.9.5779.

55. Combes V, Simon AC, Grau GE, Arnoux D, Camoin J, Sahatciu O, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. (1999) 104:93–102. doi: 10.1172/JCI9485.

56. Faille D, Combes V, Mitchell AJ, Fontaine A, Juan-Vague I, Arlesi MC, et al. Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. FASEB J. (2009) 23:3459–58. doi: 10.1096/fj.09-135822.

57. Couper KN, Barnes T, Hafalla JC, Combes V, Ryffel B, Secher T, et al. Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog. (2010) 6:e1000744. doi: 10.1371/journal.ppat.1000744.

58. Carpinettro R, Grau L, Brandt KJ, Scanu A, Faille D, Combes V, et al. HDL interfere with the binding of T cell microparticles to human monocytes to inhibit pro-inflammatory cytokine production. PLoS ONE. (2010) 5:e11869. doi: 10.1371/journal.pone.0011869.

59. Hamon Y, Brocardo C, Chambenoit O, Luciani MF, Toti F, Chalvin S, et al. ABC1 promotes engulfment of apoptotic cells and transblayer redistribution of phosphatidylserine. Nat Cell Biol. (2000) 2:399–406. doi: 10.1038/35017029.

60. Combes V, Coltel N, Alibert M, van Eck M, Raymond C, Juan-Vague I, et al. ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. Am J Pathol. (2005) 166:295–302. doi: 10.1016/S0002-9440(05)62253-5.

61. Combes V, Latham SL, Wen B, Allison AC, Grau GE, Diaennexin down-modulates TNF-induced endothelial microparticle release by blocking membrane budding process. Int J Innov Med Health Sci. (2016) 7:1–11. doi: 10.20530/ijijms.7_1-1.

62. Wassmer SC, Cianciolo GI, Combes V, Grau GE. Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med. (2005) 2:e245. doi: 10.1371/journal.pmed.0020245.

63. Penet MF, Abou-Hashem M, Coltel N, Cornille E, Grau GE, de Reggi M, et al. Protection against cerebral malaria by the low-molecular-weight thioldiamine. Proc Natl Acad Sci USA. (2005) 102:15321–6. doi: 10.1073/pnas.0706877105.

64. Pankouf Monier JK, Gouado I, Fotso Kuate H, Zambou O, Avmam Zolli PF, Grau GE, et al. Elevated cell-specific microparticles are a biological marker for cerebral dysfunctions in human severe malaria. PLoS ONE. (2010) 5:e13415. doi: 10.1371/journal.pone.0013415.

65. Nantakomol D, Dondorp AM, Kruddu S, Udomsangpeth R, Pattanapanyakasit K, Combes V, et al. Circulating red cell-derived microparticles in human malaria. J Infect Dis. (2011) 203:700–6. doi: 10.1093/infdis/jiq104.

66. Walters SB, Kieckbusch J, Nagalingam G, Swan A, Latham SL, Grau GE, et al. Microparticles from mycobacteria-infected macrophages promote inflammation and cellular migration. J Immunol. (2013) 190:669–77. doi: 10.4049/jimmunol.1201856.

67. Ramachandra L, Qu Y, Wang Y, Lewis CJ, Cobb BA, Takatsu K, et al. Mycobacterium tuberculosis synergizes with ATP to induce release of...
microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation. Infect Immun. (2010) 78:5116–25. doi: 10.1128/IAI.01089-09
75. Latham SL, Tiberti N, Gokoolparsad NH, Holdaway K, Couraud PO, Grau GE, et al. Immuno-analysis of microparticles: probing at the limits of detection. Sci Rep. (2015) 5:16314. doi: 10.1038/srep16314
76. Cohen A, Zinger A, Tiberti N, Grau GER, Combes V. Differential plasma microvesicle and brain profiles of microRNA in experimental cerebral malaria. Malar J. (2018) 17:192. doi: 10.1186/s12936-018-2330-5
77. Babatunde KA, Mbagwu S, Hernandez-Castaneda MA, Adapa SR, Walch M, Filgueira I, et al. Malaria infected red blood cells release small regulatory RNAs through extracellular vesicles. Sci Rep. (2018) 8:1884. doi: 10.1038/s41598-018-19149-9
78. Debs S, Cohen A, Hosseini-Behesti E, Chiminii G, Hunt NH, Grau GER. Interplay of extracellular vesicles and other players in cerebral malaria pathogenesis. Biochim Biophys Acta Gen Subj. (2018) 1863:325–31. doi: 10.1016/j.bbagen.2018.10.012
79. Hosseini-Behesti E, Grau GER. Extracellular vesicles as mediators of immunopathology in infectious diseases. ImmunoCell Biol. (2018) 46:694–703. doi: 10.1111/imcb.12044
80. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. (1927) 8:519–30. doi: 10.1085/jgp.8.6.519
81. Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. (2013) 15:555–64. doi: 10.1038/ncb2763
82. Laribee RN. Transcriptional and epigenetic regulation by the mechanistic target of rapamycin complex 1 pathway. J Mol Biol. (2018) 430:4874–90. doi: 10.1016/j.jmb.2018.10.008
83. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The Plasmodium sporozoite identifies B lymphocytes in the liver to initiate the immune response. J Immunol. (2001) 166:769–76. doi: 10.4049/jimmunol.166.4.769
84. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol. (2013) 14:500–8. doi: 10.1038/nm.3156
85. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeRerardins RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. (2010) 115:4742–9. doi: 10.1182/blood-2009-10-249540
86. Olenchock BA, Rathmell JC, Vander Heiden MG. Biochemical underpinnings of immune cell metabolic phenotypes. Immunity. (2017) 46:703–13. doi: 10.1016/j.immuni.2017.04.013
87. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. (2015) 33:259–83. doi: 10.1146/annurev-immunol-032712-090032
88. O’ Sullivan D, Pearce EL. Immunology. expanding the role of metabolism in T cell function. Science. (2015) 348:976–7. doi: 10.1126/science.aac4997
89. Balmer ML, Ma EH, Bantug GR, Grahlert J, Pfister S, Glatter T, et al. Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA. J Biol Chem. (2007) 282:14505–14. doi: 10.1074/jbc.M608035200
90. Penet ME, Kobez F, Confort-Gouny S, Le Fur Y, Dalmasso C, Collet N, et al. Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA. J Biol Chem. (2007) 282:14505–14. doi: 10.1074/jbc.M608035200
91. Penet ME, Viola A, Confort-Gouny S, Le Fur Y, Dalmasso C, Collet N, et al. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J Neurosci. (2005) 25:7572–8. doi: 10.1523/JNEUROSCI.1002-05.2005
92. Penet ME, Kobez F, Confort-Gouny S, Le Fur Y, Dalmasso C, Collet N, et al. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J Neurosci. (2005) 25:7572–8. doi: 10.1523/JNEUROSCI.1002-05.2005
93. Tan Z, Xie N, Cui H, Moellering DR, Abraham E, Thannickal VJ, et al. Targeting glutamine metabolism rescues mice from late-cellular resistance. Proc Natl Acad Sci USA. (2018) 115:11042–7. doi: 10.1073/pnas.1806376115
94. Covarrubias AJ, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. QJM. (1989) 71:441–59.
95. Warrell DA, White NJ, Veall N, Looareesuwan S, Chanthavanhic P, Phillips RE, et al. Cerebral anaerobic glycolysis and reduced cerebral oxygen transport in human cerebral malaria. Lancet. (1988) 2:534–8. doi: 10.1016/S0140-6736(88)92658-X
96. White NJ, Warrell DA, Looareesuwan S, Chanthavanhic P, Phillips RE, Pongpae W. Pathophysiological and prognostic significance of cerebrospinal-fluid lactate in cerebral malaria. Lancet. (1985) 1:776–8. doi: 10.1016/S0140-6736(85)90631-X
97. Hunt NH, Manduci N, Thumwood CM. Amelioration of murine cerebral malaria by dietary restriction. Parasitolology. (1993) 107:471–6. doi: 10.1046/j.1368-9130.1993.0006049X
98. Levander OA, Fontela R, Morris VC, Ager AL Jr. Protection against murine cerebral malaria by dietary-induced oxidative stress. J Parasitol. (1995) 81:99–103.
99. Gordon EB, Hart GT, Tran TM, Wasiberg M, Akkaya M, Skinner J, et al. Inhibiting the Mammalian target of rapamycin blocks the development of experimental cerebral malaria. MBio. (2015) 6:e00725-15. doi: 10.1128/MBio.00725-15
100. Meija P, Trevino-Villarreal JH, Hine C, Harputlugil E, Lang S, Calay E, et al. Dietary restriction protects against experimental cerebral malaria via leptin modulation and T-cell mTORC1 suppression. Nat Commun. (2015) 6:6050. doi: 10.1038/ncomms7050
101. Gordon EB, Hart GT, Tran TM, Wasiberg M, Akkaya M, Kim AS, et al. Targeting glutamine metabolism rescues mice from late-stage cerebral malaria. Proc Natl Acad Sci USA. (2015) 112:13075–80. doi: 10.1073/pnas.1516544112
102. Wang A, Huen SC, Luan HH, Baker K, Rinder H, Booth CJ, et al. Glucose metabolism mediates disease tolerance in cerebral malaria. Proc Natl Acad Sci USA. (2018) 115:11042–7. doi: 10.1073/pnas.1806376115
103. Munoz-Vilas J, Mello-Vieira J, Marreiros IM, Liehl P, Choraf AJ, Carret CK, et al. Dietary alterations modulate susceptibility to Plasmodium infection. Nat Microbiol. (2017) 2:1600–7. doi: 10.1038/s41564-017-0025-2
104. Wirtham M, Parker BL, Friedrichsen M, Hjorth M, Hughes WE, et al. Extracellular vesicles provide a means for tissue crosstalk during exercise. Cell Metab. (2018) 27:237–51 e4. doi: 10.1016/j.cmet.2017.12.001
105. Quintin J, Saeed S, Martens JHA, Giamarellos-Bourboulis EJ, Irfim DC, Logie WE, et al. Extracellular vesicles provide a means for tissue crosstalk during exercise. Cell Metab. (2018) 27:237–51 e4. doi: 10.1016/j.cmet.2017.12.001
106. Nota M, Grooten LA, Latz E, Mills KH, Natoili G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. (2016) 352:aaf1098. doi: 10.1126/science.aaf1098
107. Khoo KK, Mackaness GB. Macrophage proliferation in relation to acquired cellular resistance. Aust J Exp Biol Med Sci. (1964) 42:707–16.
114. Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med. (1964) 120:105–20.
115. Cheng SC, Quinlin J, Cramer RA, Shepard KM, Saeed S, Kumar V, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. (2014) 345:1250684. doi: 10.1126/science.1250684
116. Arts RJ, Novakovc B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenic programs in trained immunity. Cell Metab. (2016) 24:807–19. doi: 10.1016/j.cmet.2016.10.008
117. Dominguez-Andres J, Joosten LA, Netea MG. Induction of innate immune memory: the role of cellular metabolism. Curr Opin Immunol. (2018) 56:10–6. doi: 10.1016/j.coi.2018.09.001
118. Gupta H, Chaudhari S, Rai A, Bhat S, Sahu PK, Hande MH, et al. Genetic and epigenetic changes in host ABCB1 influences malaria susceptibility to Plasmodium falciparum. PLoS ONE. (2017) 12:e0175702. doi: 10.1371/journal.pone.0175702
119. Qdwiw T, Jamal F, Singh S. Exploring putative molecular mechanisms of human pyruvate kinase enzyme deficiency and its role in resistance against Plasmodium falciparum malaria. Interdiscip Sci. (2014) 6:158–66. doi: 10.1007/s12539-013-0025-8
120. Quin JE, Builta I, Cherif M, Sanou GS, Qu Y, Vafa Homann M, et al. Major transcriptional changes observed in the Fulani, an ethnic group less susceptible to malaria. Elife. (2017) e29156. doi: 10.7554/elife.29156
121. Schrum JE, Crabtree JN, Dobbs KR, Kirisys MC, Reed GW, Gazzinelli RT, et al. Cutting Edge: Plasmodium falciparum induces trained innate immunity. J Immunol. (2018) 200:1243–8. doi: 10.4049/jimmunol.1701010
122. Franklin BS, Parroche P, Ataide MA, Lauw F, Ropert C, de Oliveira RB, et al. Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function. Proc Natl Acad Sci USA. (2009) 106:5789–94. doi: 10.1073/pnas.0809742106
123. Dodoo D, Omer F, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis. (2002) 185:971–9. doi: 10.1086/339408
124. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis. (1999) 179:980–8. doi: 10.1086/314689
125. Horowitz A, Hafalla JC, King E, Lusingu J, Dekker D, Leach A, et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol. (2012) 188:5054–62. doi: 10.4049/jimmunol.1102710
126. McCall MB, Roestenberg M, Ploemen I, Teirlinck A, Hofman J, de Mast Q, et al. Memory-like IFN-gamma response by NK cells following malaria infection reveals the crucial role of T cells in the metabolic activation by Plasmodium falciparum. Eur J Immunol. (2010) 40:3472–7. doi: 10.1002/eji.201040587
127. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenek R, de Mast Q, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog. (2011) 7:e1002389. doi: 10.1371/journal.ppat.1002389
128. Renia L, Gruner AC, Sounou G. Cerebral malaria: in praise of epistemes. Trends Parasitol. (2010) 26:275–7. doi: 10.1016/j.pt.2010.03.005
129. Riley EM, Couper KN, Helmy H, Haifalla JC, de Souza JB, Langhorne J, et al. Neuropathogenesis of human and murine malaria. Trends Parasitol. (2010) 26:277–8. doi: 10.1016/j.pt.2010.03.002
130. de Souza JB, Haifalla JC, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology. (2010) 137:755–72. doi: 10.1017/S0031182009991715
131. Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. (2011) 10:23. doi: 10.1186/1475-2875-10-23
132. Chang-Ling T, Neill AL, Hunt NH. Early microvascular changes in murine cerebral malaria detected in retinal wholemounts. Am J Pathol. (1992) 140:1121–30.
133. Medana IM, Chan-Ling T, Hunt NH. Redistribution and degeneration of retinal astrocytes in experimental murine cerebral malaria: relationship to disruption of the blood-retinal barrier. Glia. (1996) 16:51–64.
134. White VA, Lewallen S, Beare NA, Molyneux ME, Taylor TE. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS ONE. (2009) 4:e4317. doi: 10.1371/journal.pone.0004317
135. MacCormick IJ, Beare NA, Taylor TE, Barrera V, White VA, Hiscott P, et al. Cerebral malaria in children: using the retina to study the brain. Brain. (2014) 137:2119–22. doi: 10.1093/brain/awu001
136. Barrera V, Hiscott PS, Craig AG, White VA, Milner DA, Beare NA, et al. Severity of retinopathy parallels the degree of parasite sequestration in the eyes and brains of malawian children with fatal cerebral malaria. J Infect Dis. (2015) 211:1977–86. doi: 10.1093/infdis/jiu592
137. Govindasamy G, Barber BE, Ghani SA, William T, Grigg MJ, Boroosa S, et al. Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria. J Infect Dis. (2016) 213:1476–82. doi: 10.1093/infdis/jiv746
138. Potchen MJ, Kampondeni SD, Seydel KB, Haacke EM, Sinyangwe SS, Mwenechanya M, et al. 1.5 tesla magnetic resonance imaging to investigate potential etiologies of brain swelling in pediatric cerebral malaria. Am J Trop Med Hyg. (2018) 98:497–504. doi: 10.4269/ajtmh.17-0309
139. Kampondeni SD, Birbeck GL, Seydel KB, Beare NA, Glover SJ, Hammond CA, et al. Noninvasive measures of brain edema predict outcome in pediatric cerebral malaria. Surg Neurol Int. (2018) 9:53. doi: 10.4103/sni.sni_297_17

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.